FDA Approves the First Long-acting Regimen for HIV Treatment

In COVID-19, Latest News by Precision Vaccinations

The U.S. Food and Drug Administration (FDA) announced the approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
This is the first FDA-approved injectable, complete regimen for HIV-infected adults administered once a month.

Read More